In bladder cancer, CBX7 inhibits the Aldo-keto reductase family 1 member B10 and subsequently stimulates Extracellular Signal-Regulated Kinase signaling, thereby suppressing bladder cancer progression [13]. Here, AKR1B10 is linked to urinary bladder carcinoma.